Abeona Therapeutics
ABEO
70 hedge funds and large institutions have $98.6M invested in Abeona Therapeutics in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 9 closing their positions.
4,106% more call options, than puts
Call options by funds: $4M | Put options by funds: $95K
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
38% more capital invested
Capital invested by funds: $71.6M → $98.6M (+$27M)
21% more funds holding
Funds holding: 58 → 70 (+12)
0.1% more ownership
Funds ownership: 1.43% → 1.53% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.33M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.62M |
| 3 |
CHP
Castle Hook Partners
New York
|
+$1.36M |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$1.18M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.7M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.38M |
| 3 |
PA
Perceptive Advisors
New York
|
-$1.09M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$841K |
| 5 |
NC
Nexthera Capital
New York
|
-$764K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Tudor Investment Corp
Stamford,
Connecticut
| – | -$168K | -1,340 | Closed |
|
|
HP
77
Hikari Power
Tokyo,
Japan
| – | -$150K | -1,200 | Closed |
|
|
GP
78
GLG Partners
London,
United Kingdom
| – | -$62K | -497 | Closed |
|
|
WP
79
WealthPLAN Partners
Omaha,
Nebraska
| – | -$23.9K | -186 | Closed |
|
ABEO Hedge Fund Activity: Q2 2017 in Review
70 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q2 2017, worth a combined $98.6M — up 38% from $71.6M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ABEO positions and 9 closed out — a net gain of 13 holders — while 13 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $5.33M. The largest seller was Millennium Management, exiting entirely with an estimated $1.7M sold.
- 70 institutional investors held Abeona Therapeutics (ABEO) as of Q2 2017, up from 58 in Q1 2017.
- Funds reported $98.6M of Abeona Therapeutics stock for Q2 2017, up 38% quarter-over-quarter.
- 22 funds opened new Abeona Therapeutics positions in Q2 2017 and 9 closed out, a net change of +13 holders.
- The largest Abeona Therapeutics buyer in Q2 2017 was BlackRock, an estimated $5.33M added.
- The largest Abeona Therapeutics seller in Q2 2017 was Millennium Management, an estimated $1.7M sold.
Based on aggregated 13F filings for Q2 2017.